[1] 高黎,易俊林,黄晓东,等.鼻咽癌根治性放疗10年经验总结.中华放射肿瘤学杂志,2006,15:249-256.
[2] 高黎,袁智勇,徐国镇,等.早期鼻咽癌单纯外照射与加近距离治疗的远期结果比较.中华放射肿瘤学杂志,2004,13:247-250.
[3] Baujat B,Audry H,Bourhis J,et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys,2006,64:47-56.
[4] 黄晓东,易俊林,高黎,等.同步放化疗治疗晚期鼻咽癌Ⅲ期临床研究的初步疗效分析.肿瘤学杂志,2007,15:267-271.
[5] Cao CN,Luo JW,Gao L,et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma. Oral Oncol,2013,49:175-181.
[6] Ng WT,Lee MC,Hung WM,et al.Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys,2011,79:420-428.
[7] Putti TC,To KF,Hsu HC,et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology,2002,41:144-151.
[8] Fujii M,Yamashita T,Ishiguro R,et al. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx,2002,29:175-181.
[9] Chua DT,Nicholls JM,Sham JS,et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys,2004,59:11-20.
[10] 吴润叶,高黎,杨伟志,等.头颈部癌表皮生长因子表达对预后判断价值.肿瘤学杂志,2007,13:384-387.
[11] Mason KA,Komaki R,Cox JD,et al. Biology-based combined-modality radiotherapy: workshop report.Int J Radiat Oncol Biol Phys,2001,50:1079-1089.
[12] Bonner JA,Harari PM,Giralt J,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med,2006,354:567-578.
[13] Chen CC,Zhao C,Gao L,et al. An open-labeled,multicentric clinical study of cetuximab combined with intensity-modulated radiotherapy(IMRT) plus concurrent chemotherapy in locoregionally advanced(LA)?nasopharyngeal carcinoma(NPC): a 2-year follow-up report.J Clin Oncol,2012,30(15 Suppl): 5535.
[14] Ma BB,Kam MK,Leung SF,et al. A phase Ⅱ study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol,2012,23:1287-1292.
[15] Chan AT,Hsu MM,Goh BC,et al. Multicenter,phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol,2005,23:3568-3576.
[16] 黄晓东,易俊林,高黎,等.抗表皮生长因子受体单克隆抗体h-R3联合放疗治疗晚期鼻咽癌的Ⅱ其临床研究.中华肿瘤杂志,2007,29:197-201.
[17] Chua DT,Wei WI,Wong MP,et al. Phase Ⅱ study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck,2008,30:863-867.
[18] You B,Le Tourneau C,Chen EX,et al. A Phase Ⅱ trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol,2012,35:255-260.
[19] Toi M,Matsumoto T,Bando H. Vascular endothelial growth factor: its prognostic,predictive,and therapeutic implications. Lancet Oncol,2001,2:667-673.
[20] Krishna SM,James S,Balaram P,et al. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res,2006,115:85-90.
[21] Wakisaka N,Wen QH,Yoshizaki T,et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope,1999,109:810-814.
[22] Lee NY,Zhang Q,Pfister DG,et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma(RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol,2012,13:172-180.
[23] Hui EP,Ma BB,King AD,et al. Hemorrhagic complications in a phase Ⅱ study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol,2011,22:1280-1287.
[24] Elser C,Siu LL,Winquist E,et al. Phase Ⅱ trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol,2007,25:3766-3773.
[25] Xue C,Huang Y,Huang PY,et al. Phase Ⅱ study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol,2013,24:1055-1061.
[26] Hang XF,Xu WS,Wang JX,et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol,2011,67:613-623.
[27] Je Y,Schutz FA,Choueiri TK,et al. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol,2009,10:967-974.
[28] Zuo Q,Shi M,Chen J,et al. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. Biomed Pharmacother,2011,65:168-174.
[29] Amin DN,Bielenberg DR,Lifshits E,et al. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res,2008,76:15-22.
[30] Cohen EE,Davis DW,Karrison TG,et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase Ⅰ/Ⅱ study. Lancet Oncol,2009,10:247-257.
[31] Ma BB,Lui VW,Poon FF,et al. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs,2010,28:326-333. |
|
|
2013, Vol. 22 
